Structural definition of a conserved neutralization epitope on HIV-1 gp120

Nature

Volumn 445, Issue 7129, 2007, Pages 732-737

  Zhou, Tongqing ^a   Xu, Ling ^a   Dey, Barna ^a   Hessell, Ann J ^b   Van Ryk, Donald ^a   Xiang, Shi Hua ^c   Yang, Xinzhen ^c   Zhang, Mei Yun ^d   Zwick, Michael B ^b   Arthos, James ^a   Burton, Dennis R ^b   Dimitrov, Dimiter S ^d   Sodroski, Joseph ^c   Wyatt, Richard ^a   Nabel, Gary J ^a   Kwong, Peter D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REACTION ANALYSIS; RECEPTOR BINDING; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33847101745     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05580     Document Type: Article

References (50)

1. Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strain. Science 288, 1789-1796 (2000).
2. Joint United National Programme on HIV/AIDS. 2006 Report on the global AIDS epidemic. 〈http://www.aids.org/en/HIV data/2006GlobalReport/〉 (2006).
3. Weiss, R. A. et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 316, 69-72 (1985).
4. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 280, 1884-1888 (1998).
5. Parren, P. W., Moore, J. P., Burton, D. R. & Sattentua, Q. J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 (suppl. A), S137-S162 (1999).
6. Kowalski, M. L. et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237, 1351-1355 (1987).
7. Lu, M., Blackow, S. & Kim, P. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nature Struct. Biol. 2, 1075-1082 (1995).
8. Starcich, B. R. et al. Identification and characterization of conserved and variable regions of the envelope gene HTLV-III/LAV, the retrovirus of AIDS. Cell 45, 637-648 (1986).
9. Wyatt, R. et al. The antigenic structure of the human immunodeficiency virus gp120 envelope glycoprotein. Nature 393, 705-711 (1998).
10. Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
11. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
12. Burton, D. R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2, 706-713 (2002).
13. Luftig, M. A. et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nature Struct. Mol. Biol. 13, 740-747 (2006).
14. Dalgleish, A. G. et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767 (1984).
15. Feng, F., Broder, C. C., Kennedy, P. E. & Berger, E. A. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 (1996).
16. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
17. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (1997).
18. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
19. Thali, M. et al. Characterization of conserved human immunodeficiency virus type 1 (HIV-1) gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67, 3978-3988 (1993).
20. Chen, B. et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834-841 (2005).
21. Zhang, M. Y. et al. Improved breadth and potency of an HIV-1-neutralizing singlechain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 335, 209-219 (2004).
22. Rits-Volloch, S., Frey, G., Harrison, S. C.&Chen, B. Restraining the conformation of HIV-1 gp120 by removing a flexible loop. EMBO J. 25, 5026-5035 (2006).
23. Profy, A. T. et al. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J. Immunol. 144, 4641-4647 (1990).
24. Burton, D. R. & Montefiori, D. C. The antibody response in HIV-1 infection. AIDS 11 (suppl. A), 587-598 (1997).
25. Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
26. Trkola, A. et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4 IgG. J. Virol. 69, 6609-6617 (1995).
27. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
28. Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
29. Saphire, E. O. et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
30. Sundberg, E. J. & Mariuzza, R. A. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61, 119-160 (2002).
31. Connolly, M. L. The molecular surface package. J. Mol. Graph. 11, 139-141 (1993).
32. Pantophlet, R. et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77, 642-658 (2003).
33. Zwick, M. B. et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77, 5863-5876 (2003).
34. Yang, X. et al. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J. Virol. 78, 12975-12986 (2004).
35. Arthos, J. et al. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein. Implications for therapeutic and vaccine strategies. J. Biol. Chem. 277, 11456-11464 (2002).
36. Li, Y. et al. Neutralizing specificity mapping in complex polyclonal sera (AIDS Vaccine 2006, Amsterdam, 2006).
37. Rossmann, M. G. et al. Structure of a human common cold virus and functional relationship to other picornoviruses. Nature 317, 145-153 (1985).
38. Wiley, D. C., Wilson, I. A. & Skehel, J. J. Structural identification of the antibodybinding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373-378 (1981).
39. Butters, T. D. et al. Effects of N-butyldeoxynojirimycin and the Lec3.2.8.1 mutant phenotype on N-glycan processing in Chinese hamster ovary cells: application to glycoprotein crystallization. Protein Sci. 8, 1696-1701 (1999).
40. Barouch, D. H. et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79, 8828-8834 (2005).
41. Kwong, P. D. et al. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J. Biol. Chem. 274, 4115-4123 (1999).
42. Weik, M. et al. Specific chemical and structural damage to proteins produced by synchrotron radiation. Proc. Natl Acad. Sci. USA 97, 623-628 (2000).
43. Lusty, C. J. A gentle vapor diffusion technique for cross-linking of protein crystals for cryocrystallography. J. Appl. Crystallogr. 32, 106-112 (1999).
44. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
45. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157-163 (1994).
46. McRee, D. E. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156-165 (1999).
47. Brunger, A. T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921 (1998).
48. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760-763 (1994).
49. Prabakaran, P. et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281, 15829-15836 (2006).
50. Fleury, D., Daniels, R. S., Skehel, J. J., Knossow, M. & Bizebard, T. Structural evidence for recognition of a single epitope by two distinct antibodies. Proteins 40, 572-578 (2000).